CoTherix Loss Narrows

Revenue more than doubles.
Author:
Publish date:

CoTherix

(CTRX)

reported a narrower third-quarter loss thanks to strong sales of its drug Ventavis for pulmonary arterial hypertension.

Shares were up 95 cents, or 13%, to $8.28.

The company lost $2.8 million, or 10 cents a share, in the quarter, compared with a loss of $6.2 million, or 26 cents a share, in the year-ago period.

Excluding the impact of stock-based compensation expenses and amortization of deferred stock compensation a year ago, CoTherix would have lost $1.1 million, or 4 cents a share, in the third quarter compared with a loss of $5.1 million, or 22 cents a share, a year ago.

Sales were $18.4 million, more than double last year.

The company issued 2007 sales guidance of between $100 million and $105 million. However, analysts were expecting $107 million in sales next year.